2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. CGRP Receptor
  5. CGRP Receptor Inhibitor

CGRP Receptor Inhibitor

CGRP Receptor Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-19960
    BCTC
    		Inhibitor 98.03%
    BCTC is an orally active current inhibitor of vanilloid receptor type 1 (VR1). BCTC is a transient receptor potential cation channel subfamily M member 8 (TRPM8) and transient receptor potential vanilloid 1 (TRPV1) antagonist. BCTC is an insulin sensitizer and secretor. BCTC has anticancer and analgesic effects.
  • HY-P9938
    Erenumab
    		Inhibitor
    Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine.
  • HY-P99019
    Fremanezumab
    		Inhibitor
    Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research.
  • HY-P99021
    Galcanezumab
    		Inhibitor 98.00%
    Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research.
  • HY-P99017
    Eptinezumab
    		Inhibitor 99.90%
    Eptinezumab is a human monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the receptor. Eptinezumab can be used for the prevention of migraine in adults.